The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.

The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.

Date of Patent:
Jan. 08, 2019

Filed:

Dec. 25, 2014
Applicant:

National University Corporation Kochi University, Kochi-shi, Kochi, JP;

Inventors:

Tetsuji Naka, Osaka, JP;

Satoshi Serada, Osaka, JP;

Minoru Fujimoto, Osaka, JP;

Masayoshi Toyoura, Kyoto, JP;

Yuji Shoya, Kyoto, JP;

Attorney:
Primary Examiner:
Int. Cl.
CPC ...
C07K 16/28 (2006.01); A61K 31/713 (2006.01); G01N 33/574 (2006.01); C12N 15/113 (2010.01); C07K 16/30 (2006.01); G01N 33/92 (2006.01); A61K 39/00 (2006.01);
U.S. Cl.
CPC ...
C07K 16/28 (2013.01); A61K 31/713 (2013.01); C07K 16/303 (2013.01); C07K 16/3023 (2013.01); C07K 16/3046 (2013.01); C07K 16/3069 (2013.01); C12N 15/1138 (2013.01); G01N 33/57449 (2013.01); G01N 33/57492 (2013.01); G01N 33/92 (2013.01); A61K 2039/505 (2013.01); C07K 2317/33 (2013.01); C07K 2317/34 (2013.01); C07K 2317/565 (2013.01); C07K 2317/622 (2013.01); C07K 2317/92 (2013.01); C12N 2310/14 (2013.01); G01N 2333/705 (2013.01);
Abstract

According to the present disclosure there are provided compositions and methods for treating malignant tumors, including an anti-LSR (lipolysis stimulated lipoprotein receptor) antibody that comprises the presently disclosed antibody heavy and light chain complementarity determining region (CDR) sequences, or an antigen-binding fragment thereof, or a functional equivalent thereof. Further provided for treating an LSR-positive malignancy is an LSR antagonist or an LSR inhibitor such as a nucleic acid. Therapeutic administration of the anti-LSR antibody to a subject having an LSR-positive malignant tumor is also described.


Find Patent Forward Citations

Loading…